Phaseline

Companies › SHINKEI Therapeutics

SHINKEI Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Amantadine Hydrochloride (MR-301)
Glutamate [NMDA] receptor antagonist; Matrix protein 2 inhibitor
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Traumatic Brain Injury–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06253923Amantadine Hydrochloride (MR-301)Phase 2Traumatic Brain InjuryNeurologyJul 2025

Targets

GRIN1 (1) GRIN2A (1) GRIN2B (1) GRIN2D (1) GRIN3B (1)

Companies with the same targets

Johnson & Johnson (Janssen) Syndeio Biosciences Aptinyx GRIN Therapeutics Praxis Precision Medicines Arialys Australia atai Therapeutics Exciva CSPC Ouyi Pharmaceutical Neuren Pharmaceuticals

Companies built like this

Aptinyx Exciva Neuron23 Bial R&D Investments NeuroTherapia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.